Vincent Venincasa, MD
Ophthalmology · Edmond, OKNPI 1154709970
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,662 of the $5,432 with a category attached, or 85.8%. It is spread thinly across 18 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,287 and has fallen 51.6% since, to $623 in 2025.
Across 113 payments — averaging $48.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$952
- Alcon$845
- Bausch & Lomb Americas Inc.$783
- Glaukos Corporation$700
- Notal Vision, Inc.$660
- AbbVie$528
- plus $964 from 12 others
What the payments were for
- Speaking & faculty fees$77014%
- Food & beverage$4,66286%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $952 |
| Alcon | 18 | $845 |
| Bausch & Lomb Americas Inc. | 16 | $783 |
| Glaukos Corporation | 7 | $700 |
| Notal Vision, Inc. | 1 | $660 |
| AbbVie(2 entities) | 21 | $528 |
| Rxsight Inc | 6 | $369 |
| Biotissue Holdings Inc. | 8 | $160 |
| Sun Pharmaceutical Industries Inc. | 6 | $126 |
| Novartis | 5 | $90 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Tarsus Pharmaceuticals, Inc. | 2 | $43 |
| NEW World Medical,inc. | 2 | $23 |
| Dompe US, Inc. | 1 | $21 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
| Thea Pharma Inc. | 1 | $18 |
| Harrow Eye, LLC | 1 | $16 |
| Sight Sciences, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$595
- RXSIGHT CONTACT LENS$257
- RXSIGHT INJECTOR CARTRIDGE$257
- RXSIGHT INJECTOR HANDPIECE$257
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$257
- Centurion$148
- LIGHT ADJUSTABLE LENS (LAL)$141
- Clareon$135
- iStent Trabecular Micro-Bypass System Model iS3$134
- iStent inject W$125
- KXL System$125
- Photrexa$125
- STELLARIS$124
- iStent inject Trabecular Micro-Bypass Stent System$124
- iDose$124
- TORIC$121
- ENVISTA$121
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$116
- AcrySof IQ PanOptix UV IOL$116
- ENVISTA ENVY IOL$113
How this compares
$5,432 in reported general payments places this provider in the 85th percentile of 183 ophthalmology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 21 | $27,424 |
| VyzultaLatanoprostene Bunod | 44 | $13,479 |
| LumiganBimatoprost | 15 | $5,630 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $4,444 |
| Prednisolone Acetate | 31 | $1,415 |
| Latanoprost | 199 | $1,015 |
| Travoprost | 11 | $897 |
| Brimonidine Tartrate | 25 | $295 |
| Timolol Maleate | 46 | $125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $783 | $40,90465 claims |
| AbbVieLumigan | $528 | $5,63015 claims |
| AlconSimbrinza | $845 | $4,44422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 183 ophthalmology providers in Oklahoma.
Other ophthalmology in Edmond
- Don NguyenEdmond$36K
- Bradley BrittonEdmond$25K
- Jeffrey ShaverEdmond$11K
- Whitney PotterEdmond$10K
- Michael HogueEdmond$6K
- Jared JacksonEdmond$3K
- Brian MorganEdmond$3K
- Ronald RebenitschOklahoma City$141K
- Kyle RogersEnid$19K
- Edward JonesOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.